Core Viewpoint - The company reported strong financial results for 1H2025, with revenue and profit growth exceeding expectations, leading to an upward revision of the annual performance guidance [1] Financial Performance - 1H2025 revenue reached 20.799 billion yuan, a year-on-year increase of 20.64%, with continuous operations revenue at 20.405 billion yuan, up 24.24% [1] - The net profit attributable to the parent company, excluding non-recurring items, was 5.582 billion yuan, reflecting a growth of 26.47%, while the adjusted net profit was 6.315 billion yuan, up 44.43% [1] - In Q2 alone, revenue was 11.145 billion yuan, a 20.37% increase year-on-year, with adjusted net profit rising to 3.637 billion yuan, a significant increase of 47.90% [1] Business Segments - The chemical segment generated 16.3 billion yuan in 1H2025, a 33.5% increase, driven by strong growth in TIDES and small molecule D&M revenues [2] - TIDES revenue reached 5.03 billion yuan, up 141.6%, with small molecule D&M revenue at 8.68 billion yuan, increasing by 17.5% [2] - The Testing segment reported 2.69 billion yuan in revenue for 1H2025, a slight decline of 1.2%, but showed signs of recovery in Q2 with a 1.6% year-on-year increase [2] - The Biology segment achieved 1.25 billion yuan in revenue, a 7.5% increase, with expectations for accelerated growth as new molecular development demands rise [3] Profitability and Efficiency - The adjusted gross margin for 1H2025 was 44.5%, an increase of 4.7 percentage points [3] - The gross margins for the chemical, Testing, and Biology segments were 49%, 25.1%, and 36.4%, respectively, with the chemical segment benefiting from increased commercial projects [3] Future Outlook - The company has raised its full-year revenue guidance, expecting 2025 revenue to reach between 42.5 billion and 43.5 billion yuan, representing a growth of 13% to 17% [1] - Revenue projections for 2025-2027 are estimated at 43.771 billion, 50.810 billion, and 59.066 billion yuan, with corresponding year-on-year growth rates of 11.54%, 16.08%, and 16.25% [3]

Core Viewpoint - WuXi AppTec (药明康德) has reported its best-ever half-year performance for 2025, with significant revenue and profit growth driven by investment gains and reduced expenses [2][3][4]. Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.799 billion yuan, a year-on-year increase of 20.64% [4][5]. - The net profit attributable to shareholders reached 8.561 billion yuan, marking a year-on-year growth of 101.92%, the first time the company has doubled its net profit in the first half since its A-share listing [4][9]. - Investment income for the first half of 2025 was 3.669 billion yuan, significantly up from 22 million yuan in the same period last year, primarily due to the sale of shares in an associate company [9]. Cost Management - WuXi AppTec has successfully reduced management and R&D expenses in the first half of 2025, with management expenses at 1.175 billion yuan and R&D expenses at 514 million yuan, both showing a decrease compared to the previous year [3][10]. - Sales expenses were 394 million yuan, accounting for 1.89% of revenue, down from 2.08% in the previous year [10]. Business Segments - The chemical business generated 16.3 billion yuan in revenue, a 33.5% increase year-on-year, while the small molecule drug discovery business contributed 8.68 billion yuan, up 17.5% [6]. - The TIDES business saw remarkable growth, with revenue reaching 5.03 billion yuan, a 141.6% increase [6]. - The testing business generated 2.69 billion yuan, with laboratory analysis and testing contributing 1.89 billion yuan, a slight increase of 0.4% [6]. Regional Performance - Revenue from U.S. clients was 14.03 billion yuan, up 38.4%, while European clients contributed 2.33 billion yuan, a 9.2% increase. Revenue from Chinese clients decreased by 5.2% to 3.15 billion yuan [7]. Future Outlook - WuXi AppTec has raised its full-year revenue guidance for 2025, expecting a growth rate of 13% to 17%, up from the previous estimate of 10% to 15% [7]. - The company reported a backlog of 56.69 billion yuan in ongoing business, a 37.2% increase year-on-year, indicating strong future demand [8]. Market Reaction - Following the impressive half-year results, WuXi AppTec's A-shares rose by 7.72% and H-shares increased by 11.25% on July 28 [12].

据证券之星公开数据整理，近期药明康德（603259）发布2025年中报。截至本报告期末，公司营业总收入207.99亿元，同比上升20.64%，归母净利润85.61亿元，同比上升101.92%。按单 本次财报公布的各项数据指标表现尚佳。其中，毛利率44.45%，同比增12.91%，净利率41.64%，同比增67.69%，销售费用、管理费用、财务费用总计17.76亿元，三费占营收比8.54%，同 | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 172.41亿 | 207.99亿 | 20.64% | | 归母净利润（元） | 42.41Z | 85.61亿 | 101.92% | | 扣非净利润(元) | 44.14 Z | 55.82 G | 26.47% | | 货币资金(元) | 146.72亿 | 214.85亿 | 46.44% | | 应收账款(元) | 76.14亿 | 70.32 亿 | -7.64% | | 有息负债(元) | 60.46亿 | 69.24亿 | 14.52% | | 毛利率 | 3 ...

Core Viewpoint - The company has adjusted the upper limit for the repurchase price of its shares from 90.72 RMB to 114.15 RMB per share, reflecting confidence in its future development and the recognition of its value [1][4]. Group 1: Basic Situation of Share Repurchase - The company received general authorization from the shareholders' meetings held on April 29, 2025, to repurchase A-shares and/or H-shares [2]. - The total amount allocated for the repurchase is 1 billion RMB, with a repurchase period not exceeding 12 months from the approval date [2]. Group 2: Progress of Share Repurchase - As of July 28, 2025, the company has repurchased a total of 6,514,425 A-shares, accounting for 0.23% of the total share capital, with an average repurchase price of 76.34 RMB per share [3]. Group 3: Specifics of Price Adjustment - The adjustment of the repurchase price limit to 114.15 RMB per share is based on the average trading price of the company's shares over the previous 30 trading days, set at 150% of that average [4]. Group 4: Impact of Price Adjustment - The adjustment complies with relevant regulations and is expected to facilitate the smooth implementation of the repurchase plan without adversely affecting the company's operations, financial status, or future development [5][6].

今年以来，创新药迎来一波火热行情，赋能医药研发与生产的医药外包企业也出现回暖迹象。7月29 日，医药外包龙头企业药明康德（603259）交出了一份史上最强中报。 药明康德2025年半年度报告显示，公司上半年实现营业收入约为207.99亿元，同比增长20.64%；对应实 现的归属净利润约为85.61亿元，同比增长101.92%；扣非净利润约为55.82亿元，同比增长26.47%。公 司营收、净利均创下历史新高。 受这一消息影响，7月29日，药明康德A股、H股双双大涨，股价均创下年内新高。其中药明康德A股收 涨7.72%，收盘价为98.69元/股，总市值为2835亿元，全天成交金额90.14亿元，换手率为3.78%。药明康 德H股收涨11.25%，收盘价为111.7港元/股。 今年4月以来，药明康德股价持续上涨。东方财富显示，4月10日—7月29日，药明康德A股后复权形式 下区间累计涨幅为89.65%。 股价持续上涨之下，7月29日晚间，药明康德公告称，公司拟将2025年第一次以集中竞价交易方式回购 A股股份的回购股份价格上限由不超过90.72元/股调整为不超过114.15元/股。 药明康德董事长兼首席执行官李革 ...

（文章来源：证券日报） 证券日报网讯 7月29日晚间，药明康德发布公告称，公司于2025年7月29日召开第三届董事会第二十三 次会议，审议通过了《关于调整回购股份价格上限的议案》，公司拟将2025年第一次以集中竞价交易方 式回购A股股份（以下简称"本次回购"）的回购股份价格上限由不超过90.72元/股（含）调整为不超过 人民币114.15元/股，本次回购方案的其他内容不变。 ...

药明康德本月股价涨幅已达41.90%。在昨日发布营收、净利均同比双位数增长的半年报后，今日药明 康德A股上涨7.72%，报收98.69元/股；H股上涨11.25%，报收111.70港元/股。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经7月29日讯（记者 武超 卢阿峰）近阶段，医药板块持续升温，频频释放利好的药明康德 （603259.SH）股价也持续攀升，现已恢复至3年前的位置。而公司今晚一则"调高回购股份价格上限"的 公告，则进一步显露出对未来的信心。 据公告，药明康德拟将2025年第一次以集中竞价交易方式回购A股股份的回购股份价格上限由不超过 90.72元/股（含）调整为不超过114.15元/股，即不高于董事会通过本次决议前30个交易日公司股票交易 均价的150%。 此前，药明康德审议通过《关于2025年以集中竞价交易方式回购公司A股股份的议案》，同意公司以总 额为10亿元的自有资金和自筹资金、以集中竞价交易方式回购公司 ...

药明康德还宣布中期分红方案，共计约为10亿元，拟每10股派发现金红利3.5元。2025年以来，公司现 金分红与回购注销规模达到近70亿元。 新京报贝壳财经讯 药明康德（603259）发布2025年半年报，报告期内，公司实现营业收入207.99亿元， 同比增长20.64%；归属于上市公司股东的净利润85.6亿元，同比增长101.92%。 ...

把握中国龙头药企价值重估机遇，配置工具关注国内首只药ETF（562050）。聚焦A股50大龙头药企， 重仓创新药，兼顾高壁垒仿制药及中药，且完全不含医疗和CXO。 分析人士指出，药明康德上半年营业收入、净利润均创下历史新高，第二季度单季营收首次站上百亿元 台阶，达到111.45亿元。作为CXO"一哥"，逆势交出"最强"中报，向市场注入"强心剂"，并印证行业或 正加速回暖。 中金公司指出，如今创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求 起量以及一级创新药项目融资活跃度提升，内需CRO有望受益。另一方面，中国企业成本与效率优势 对海外客户具较强吸引力，外需CDMO订单趋势同样向好。 药明康德交出"史上最强"半年报，CXO板块沸腾！医疗ETF（512170）覆盖的6只CXO龙头股集体上 攻，药明康德涨7.72%，股价逼近100元，创3年新高！成交90.14亿元，位列A股第7。此外，九洲药业 涨停，昭衍新药午后触板。 中泰证券提示，随着财报陆续披露，CXO、GLP-1等景气赛道表现亮眼。后续建议继续重点关注有望逐 步走出拐点的细分板块，如CXO、科研上游等。 把握CXO、医疗器械拐点向上 ...

今年以来，创新药迎来一波火热行情，赋能医药研发与生产的医药外包企业也出现回暖迹象。7月29日，医药外包龙头企业药明康德 （603259）交出了一份史上最强中报。 药明康德2025年半年度报告显示，公司上半年实现营业收入约为207.99亿元，同比增长20.64%；对应实现的归属净利润约为85.61亿 元，同比增长101.92%；扣非净利润约为55.82亿元，同比增长26.47%。公司营收、净利均创下历史新高。 | | | | 早刊: 九 川州: 八尺川 | | --- | --- | --- | --- | | 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上 | | | (1-6月) | | 年同期增减(%) | | 营业收入 | 20,799,281,882.46 | 17,240,918,263.02 | 20.64 | | 利润总额 | 9.907.416.557.97 | 5.049.553.770.35 | 96.20 | | 归属于上市公司股东的净利润 | 8.560.882.627.56 | 4.239.822.013.11 | 101.92 | | 归属于上市公司股东的扣除非经常 | ...